Hara Capital LLC Buys Shares of 265 Becton, Dickinson and Company (NYSE:BDX)

Hara Capital LLC bought a new stake in Becton, Dickinson and Company (NYSE:BDX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 265 shares of the medical instruments supplier’s stock, valued at approximately $64,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BDX. Livelsberger Financial Advisory bought a new position in Becton, Dickinson and Company in the third quarter valued at about $26,000. Sound Income Strategies LLC grew its position in Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 44 shares during the last quarter. Opal Wealth Advisors LLC bought a new position in Becton, Dickinson and Company in the second quarter valued at about $45,000. Abound Wealth Management grew its position in Becton, Dickinson and Company by 96.0% in the second quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after acquiring an additional 96 shares during the last quarter. Finally, Chilton Capital Management LLC grew its position in Becton, Dickinson and Company by 1,233.3% in the second quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock valued at $47,000 after acquiring an additional 185 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $226.97 on Friday. The stock’s 50 day moving average is $237.53 and its 200 day moving average is $235.16. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The firm has a market cap of $65.60 billion, a P/E ratio of 46.70, a P/E/G ratio of 1.76 and a beta of 0.43. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $257.58.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 EPS for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The firm’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the firm earned $3.42 earnings per share. As a group, research analysts expect that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be paid a $1.04 dividend. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a yield of 1.83%. Becton, Dickinson and Company’s payout ratio is 78.19%.

Analyst Ratings Changes

A number of brokerages have recently commented on BDX. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Raymond James cut their price target on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Evercore ISI lifted their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price target for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Finally, Stifel Nicolaus lifted their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Buy” and a consensus target price of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.